other · Figshare
Abstract Background Pulmonary hypertension (PH) is a serious and potentially life-threatening complication of systemic lupus erythematosus (SLE). Functional characterization may facilitate the differentiation of the heterogeneous phenotypes of systemic lupus erythematosus–associated pulmonary hypertension (SLE-PH). Methods Sixty patients with SLE-PH were prospectively analyzed and classified into four groups: SLE-associated pulmonary arterial hypertension (SLE-PAH; n = 15), SLE with left ventricular (LV) dysfunction (n = 20), SLE with interstitial lung disease–associated pulmonary hypertension (ILD-PH; n = 21), and chronic thromboembolic pulmonary hypertension (CTEPH; n = 4). Spirometric, echocardiographic, and clinical variables were compared using one-way analysis of variance (ANOVA) with least significant difference (LSD) post-hoc testing and Fisher’s exact test. Results Airflow indices were comparable across groups. In contrast, forced vital capacity (FVC) differed significantly (p = 0.017), with reduced values observed in the ILD-PH subgroup. The LV dysfunction subgroup demonstrated markedly reduced ejection fraction (EF) (p < 0.001) and elevated estimated pulmonary artery pressure (EPAP) (p = 0.037). Post-hoc analysis identified significant pairwise differences in forced expiratory volume in 1 s (FEV₁), FEV₁/FVC ratio, and EPAP. Dyspnea severity also differed significantly among groups (p = 0.018). Conclusions SLE-PH demonstrates distinct cardiopulmonary functional phenotypes. The combined use of spirometry and echocardiography provides a practical, non-invasive approach for early phenotypic characterization, with potential implications for risk stratification and individualized management.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.6084/m9.figshare.c.8454600.v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.